Mentice AB (MNTC) AI Stock Analysis

• Market Cap: €411.66M
• Dividend Yield: N/A
• Average Volume (3M): 15.51K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.74
• Revenue Growth: 17.75%
• EPS Growth: 18.05%
• Country: SE
• Employees: 131
• Sector: Technology
• Sector Strength: 78
• Industry: Medical - Devices
• EPS (TTM): -1.09
• Shares Outstanding: 25,568,850
• 10 Day Avg. Volume: 7,014
• 30 Day Avg. Volume: 15,511
• PEG Ratio: -9.17
• Price to Book (P/B): 5.86
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 514.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 50 Neutral
• Price Target: kr17.50 ▲(8.70%Upside)

Mentice AB's overall stock score is impacted primarily by its financial performance, which reflects revenue growth but significant profitability challenges. Technical analysis indicates mixed signals with some bearish trends. Valuation concerns due to negative earnings and no dividend further weigh on the score. The absence of earnings call data and corporate events leaves these factors unaddressed.

Mentice AB Business Overview & Revenue Model

Company Description

Mentice AB (MNTC) is a global leader in medical simulation solutions, specializing in the development of high-fidelity virtual reality-based training systems for healthcare professionals. The company focuses primarily on endovascular procedures, offering products that help medical practitioners enhance their skills and improve patient outcomes. With a strong emphasis on innovation, Mentice provides a range of simulators designed to replicate real-life surgical scenarios, thus aiding in the education and training of surgeons and medical students worldwide.

How the Company Makes Money

Mentice AB generates revenue through the sale of its medical simulation solutions, which include high-tech simulators for various endovascular procedures. The company's primary revenue streams are derived from direct sales to healthcare institutions, including hospitals, medical universities, and training centers. Additionally, Mentice offers subscription-based software licenses and maintenance contracts, providing ongoing technical support and updates for their products. The company also partners with medical device manufacturers to develop integrated training solutions, which can further contribute to its revenue. These collaborations enable Mentice to offer customized training modules that complement specific medical devices, thereby enhancing its value proposition to customers.

Mentice AB Financial Statement Overview

Summary

Mentice AB demonstrates revenue growth, but faces significant profitability challenges with consistent net losses and negative profit margins. The balance sheet shows low leverage, reducing financial risk, yet negative return on equity is concerning. Cash flow generation is weak, especially in free cash flow, indicating potential difficulties in sustaining growth.

Income Statement

Mentice AB's income statement shows mixed results. While there is a positive trend in revenue growth, with TTM revenue increasing by 3.04% from the previous year, profitability remains a concern. The company has consistently reported net losses, and the TTM net profit margin is negative at -7.11%. EBITDA margin stands at 5.90%, indicating some operational efficiency, but EBIT margin is negative, highlighting ongoing challenges in covering operating expenses.

Balance Sheet

The balance sheet reflects a stable equity position with a debt-to-equity ratio of 0.18, indicating low leverage and reduced financial risk. However, the equity ratio has slightly decreased to 38.72%, suggesting a marginal decline in the proportion of assets financed by equity. The return on equity is negative, at -18.59%, due to ongoing net losses, which is a concern for shareholder value.

Cash Flow

Mentice AB's cash flow statement reveals challenges in generating free cash flow, with a negative TTM free cash flow of -3.75 million. The operating cash flow to net income ratio is positive at -0.60, indicating some ability to convert income into cash flow. However, the free cash flow to net income ratio remains negative, suggesting difficulty in maintaining cash flow after capital expenditures.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
299.17M	290.33M	273.61M	217.95M	185.06M	137.50M
	Gross Profit
265.02M	257.25M	236.38M	188.94M	149.92M	104.11M
	EBIT
-14.99M	-12.40M	-679.00K	-22.67M	-18.51M	-31.59M
	EBITDA
17.65M	18.30M	28.87M	266.00K	1.44M	-3.90M
	Net Income Common Stockholders
-21.29M	-18.42M	-2.82M	-30.66M	-29.19M	-13.09M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
40.55M	53.59M	59.12M	47.28M	12.70M	48.75M
	Total Assets
295.65M	323.90M	322.53M	332.98M	261.90M	245.27M
	Total Debt
20.75M	9.14M	9.56M	16.68M	14.70M	11.51M
	Net Debt
-19.80M	-44.45M	-49.56M	-30.61M	2.01M	-37.24M
	Total Liabilities
181.13M	180.24M	163.55M	170.34M	125.02M	82.02M
	Stockholders Equity
114.52M	143.66M	158.97M	162.63M	136.89M	163.25M
Cash Flow		Free Cash Flow
-3.75M	1.48M	29.53M	1.85M	-31.03M	5.20M
	Operating Cash Flow
12.67M	17.92M	36.52M	14.91M	-5.13M	30.53M
	Investing Cash Flow
-16.42M	-16.44M	-16.18M	-32.28M	-25.90M	-24.97M
	Financing Cash Flow
-11.16M	-9.31M	-7.05M	48.99M	-5.78M	-3.98M

Mentice AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 16.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:MNTC, the sentiment is Negative. The current price of 16.1 is below the 20-day moving average (MA) of 17.48, below the 50-day MA of 18.47, and below the 200-day MA of 23.51, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 38.86 is Neutral, neither overbought nor oversold. The STOCH value of 5.03 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:MNTC.

Mentice AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRAD.B	72 Outperform	kr1.18B	36.43	10.11%	―	2.53%	-44.90%
Sector *	62 Neutral	$11.80B	10.08	-7.46%	2.99%	7.37%	-8.21%
SEDANA	55 Neutral	kr1.04B	―	-5.61%	―	13.66%	-139.90%
INTEG.B	53 Neutral	kr465.09M	―	-19.17%	―	-12.50%	-783.92%
MNTC	50 Neutral	€411.66M	―	-17.16%	―	17.75%	18.05%
ACARIX	46 Neutral	kr254.23M	―	-88.97%	―	-0.61%	54.19%
BACTI.B	46 Neutral	kr1.04B	―	-7.30%	―	23.51%	80.47%